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Abstract
Background: Severe outcomes have been described for both Plasmodium falciparum and P. vivax infections. The
identification of sensitive and reliable markers of disease severity is fundamental to improving patient care. An intense pro-
inflammatory response with oxidative stress and production of reactive oxygen species is present in malaria. Inflammatory
cytokines such as tumor necrosis factor-alpha (TNF-alpha) and antioxidant agents such as superoxide dismutase-1 (SOD-1)
are likely candidate biomarkers for disease severity. Here we tested whether plasma levels of SOD-1 could serve as a
biomarker of severe vivax malaria.
Methodology/Principal Findings: Plasma samples were obtained from residents of the Brazilian Amazon with a high risk for
P. vivax transmission. Malaria diagnosis was made by both microscopy and nested PCR. A total of 219 individuals were
enrolled: non-infected volunteers (n=90) and individuals with vivax malaria: asymptomatic (n=60), mild (n=50) and severe
infection (n=19). SOD-1 was directly associated with parasitaemia, plasma creatinine and alanine amino-transaminase
levels, while TNF-alpha correlated only with the later enzyme. The predictive power of SOD-1 and TNF-alpha levels was
compared. SOD-1 protein levels were more effective at predicting vivax malaria severity than TNF-alpha. For discrimination
of mild infection, elevated SOD-1 levels showed greater sensitivity than TNF-alpha (76% vs. 30% respectively; p,0.0001),
with higher specificity (100% vs. 97%; p,0.0001). In predicting severe vivax malaria, SOD-1 levels exhibited higher sensitivity
than TNF-alpha (80% vs. 56%, respectively; p,0.0001; likelihood ratio: 7.45 vs. 3.14; p,0.0001). Neither SOD-1 nor TNF-alpha
could discriminate P. vivax infections from those caused by P. falciparum.
Conclusion: SOD-1 is a powerful predictor of disease severity in individuals with different clinical presentations of vivax
malaria.
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Introduction
Severe malaria presents a relevant public health problem
worldwide, affecting the socio-economic development of many
communities. The identification of predictors of disease severity is
critical to improve patient care. Most of the actual knowledge
regarding the immunopathological determinants of malaria
severity refers to infection caused by Plasmodium falciparum, but
growing evidence also associates vivax malaria with severe
complications [1,2]. Together with rising documentation of drug
resistance worldwide, the complications of Plasmodium vivax
infection represents a global health threat. Therefore, identifying
markers of disease severity is essential to improve clinical
management. Plasma TNF-alpha levels have been described as a
biomarker for the estimation of disease severity for P. falciparum [3]
and is associated with clinical severity in P. vivax [4] infections, but
there is scarce data evaluating or validating more sensitive and
reliable predictors of severe disease.
During malaria infection, reactive oxygen species (mainly
superoxide anions) are produced at high levels, inducing parasite
killing and tissue damage [5]. To circumvent this biological injury,
the anti-oxidant enzyme Cu/Zn superoxide dismutase (SOD-1)
converts these unstable free radicals into hydrogen peroxide
(H2O2), which can be removed by the catalase and glutathione
systems [6]. Studies in both mice [7] and humans [8] have
correlated the SOD-1 activity with tissue damage. Therefore,
investigating markers related to oxidative stress could provide
useful tools to manage malaria. The present work shows that the
plasma level of SOD-1 is a surrogate marker of severe vivax
malaria in a population from the Brazilian Amazon, in which P.
vivax infection is highly endemic. The performance of SOD-1 as a
predictor of disease severity even surpasses that of TNF-alpha.
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Objective
The objective of this study was to test whether the plasma level
of SOD-1, an antioxidant enzyme, could predict vivax malaria
severity with equivalent of better efficacy compared to the
currently used marker TNF-alpha.
Study design and participants
Plasma samples were obtained from individuals living in Buritis,
a recently urbanized municipality in Rondo ˆnia, Brazilian
Amazon, with a high risk for vivax malaria transmission [9],
during June 2006 and August 2007. Active and passive malaria
case detections were performed. These included home visits and
study of individuals who sought care at the diagnostic center of
Brazilian National Foundation of Health (FUNASA). In addition,
patients admitted to the Buritis municipal Hospital with clinical
signs of mild or severe malaria [10] were also asked to participate
in the study. All individuals from fifteen to seventy years, of both
sexes, who had been living in the endemic area for more than six
months, were invited to be included in the study. The malaria
diagnosis was performed using two methods (double-blinded).
First, patients were screened by thick smear examination using
field microscopy and the parasitaemia (parasites/uL) was quanti-
fied in positive cases. Further, nested PCR was performed in all
Author Summary
Despite being considered a relatively benign disease,
Plasmodium vivax infection has been associated with fatal
outcomes due to treatment failure or inadequate health
care. The identification of sensitive and reliable markers of
disease severity is important to improve the quality of
patient care. Although not imperative, a good marker
should have a close causative relationship with the disease
pathogenesis. During acute malaria, an intense inflamma-
tory response and a well-documented oxidative burst are
noted. Among the free radicals released, superoxide
anions account for the great majority. The present study
aimed to evaluate the reliability of using an antioxidant
enzyme, responsible for the clearance of superoxide
anions, as a marker of vivax malaria severity. Thus, we
investigated individuals from an Amazonian region highly
endemic for vivax malaria with the goal of predicting
infection severity by measuring superoxide dismutase-1
(SOD-1) plasma levels. In addition, we compared the
predictive power SOD-1 to that of the tumor necrosis
factor (TNF)-alpha. SOD-1 was a more powerful predictor
of disease severity than TNF-alpha in individuals with
different clinical presentations of vivax malaria. This finding
opens up new approaches in the initial screening of severe
vivax malaria cases.
Table 1. Baseline characteristics of the participants.
Variables Plasmodium vivax infection
Non-infected Asymptomatic Mild Severe
N=90 N=60 N=50 N=19
Male – no. (%) 39 (43.3) 30 (50.0) 22 (44.0) 10 (52.6)
Age – year*
Median 38.0 42.0 33.0 22.0
Interquartile interval 25.0–51.0 32.0–48.2 26.7–48.0 16.0–35.0
Parasitaemia (parasites/uL)*
Median 0 73 4,798 49,358
Interquartile interval 0 54.0–85.0 2,934–7,483 32,796–54,244
Haemoglobin (g/dL)*
Median 13.2 11.5 8.9 6.4
Interquartile interval 9.2–14.5 9.5–14.2 7.3–12.6 5.8–7.4
Serum creatinine (mg/dL)*
Median 0.85 0.9 1.1 1.7
Interquartile interval 0.7–1.2 0.7–1.2 0.7–1.3 1.42–2.45
ALT (U/L)*
Median 42.35 40 58.3 238.4
Interquartile interval 37.28–53.58 23.25–65.78 43.6–87.5 105.5–364.6
UNL 1.06 1 1.46 4.96
Clinical presentation – no. (%)
1*
Splenomegaly - - 8 (16.0) 6 (31.6)
Hypotension - - 6 (12.0) 14 (73.68)
Jaundice - - 9 (18.0) 7 (36.8)
ALT: alanine amino-transferase. UNL: Upper normal levels. Data represent the number of times the median of ALT is higher than the standardized normal laboratory
level (40U/L). Ordinal variables were compared using the Kruskal Wallis test with Dunn’s multiple comparisons. The prevalence of male gender was compared between
the groups using chi-square test.
*Differences were significant between groups (P,0.05).
1The groups were compared using chi-square test.
doi:10.1371/journal.pntd.0000650.t001
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were viral hepatitis (A, B, C, and D), chronic alcoholism, human
immunodeficiency virus type 1 infection, yellow fever, leptospiro-
sis, cancer and chronic degenerative diseases, sickle cell trait and
the use of hepatotoxic or immunosuppressant drugs. Two
individuals presenting P. malariae infection were identified and
excluded from the study. In addition, 16 age-matched people
infected with P. falciparum (uncomplicated forms) were invited to
participate. In the last phase of the study, plasma samples from
these individuals with P. falciparum malaria were used in order to
assess if the markers compared were useful to discriminate P. vivax
from P. falciparum infections.
After obtaining the parasitological diagnosis, all vivax malaria
positive cases were followed for 30 days. Individuals infected with
P. falciparum were not included in the follow up. Infected
individuals who remained without any presumptive malaria
symptoms were considered asymptomatic; patients presenting
clinical or laboratory signs of complicated malaria [10] were
considered severe cases, while those who were symptomatic
without any complication were mild cases. In hospitalized
participants presenting with severe disease, two plasma samples
were obtained: one at the hospital admission and other seven days
after malaria treatment initiation. Thus, of 415 individuals initially
approached, 58 were excluded for meeting exclusion criteria, 86
withdrawn consent and 36 neglected the follow up. The sample
was then composed of non-infected volunteers (n=90) and
individuals with different clinical presentations of vivax malaria:
asymptomatic (n=60), mild (n=50) and severe infection (n=19).
The detailed clinical descriptions of the participants together with
the outcomes have been already addressed by our group [11]. A
summary of the baseline characteristics of the participants is
illustrated in Table 1. All the malaria cases were treated by the
FUNASA health care professionals according to the FUNASA
standardized protocols. The flow chart of the validation study is
shown in Figure S1.
Ethics statement
Written informed consent was obtained from all participants,
and all clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki. The project
was approved by the institutional review board of the Faculdade
de Medicina, Faculdade Sa ˜o Lucas, Rondo ˆnia, Brazil, where the
study was performed.
Nested PCR for malaria diagnosis
The molecular diagnosis of malaria was performed using nested
PCR, as described previously [12]. Briefly, 300 mL of whole blood
collected on EDTA was prepared for DNA extraction through the
phenol-chloroform method followed by precipitation with sodium
acetate and ethanol. The first PCR rDNA amplification was
performed with Plasmodium genus-specific primers named PLU5
and PLU6. Positive samples yielded a 1,200-bp fragment, which
served as template for the nested reaction. The nested PCR
Table 2. Primers used in Nested PCR reactions.
Primer Oligonucleotide Sequence 59-39 Base Pairs
PLU5 CCTGTTGTTGCCTTAAACTTC 1,200
PLU6 TTAAAATTGTTGCAGTTAAAA
Fal1 TTAAACTGGTTTGGGAAAACCAAATATATT 205
Fal2 ACACAATGAACTCAATCATGACTACCCGTC
Viv1 CGCTTCTAGCTTAATCCACATAACTGATAC 120
Viv2 ACTTCCAAGCCGAAGCAAAGAAAGTCCTTA
Mal1 ATAACATAGTTGTACGTTAAGAATAACCGC 144
Mal2 AAAATTCCCATGCATAAAAAATTATACAAA
PLU: Plasmodium sp, Fal: Plasmodium falciparum, Viv: Plasmodium vivax, Mal:
Plasmodium malariae.
doi:10.1371/journal.pntd.0000650.t002
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Figure 1. Plasma SOD-1 and TNF-alpha as markers of severe
vivax malaria. A, SOD-1 protein and TNF-alpha plasma levels
according to vivax malaria clinical severity. NI, non-infected volunteers
(n=90); Asy, asymptomatic infection (n=60); Sympt, symptomatic
infection (n=69). Differences among the groups were calculated using
the Kruskal Wallis analysis of variance with Dunn’s multiple comparisons
test. B, Plasma levels of SOD-1 and TNF-alpha in individuals with mild P.
vivax infection (n=50) compared to those with severe vivax malaria
(Sev; n=19). Boxes represent median and interquartile interval;
whiskers represent maximum and minimum values. Differences were
estimated using Mann-Whitney test. Lines represent median values. P
values are shown in each graph.
doi:10.1371/journal.pntd.0000650.g001
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www.plosntds.org 3 April 2010 | Volume 4 | Issue 4 | e650amplification was performed with species-specific primers for 30
cycles at annealing temperatures of 58uC for P. falciparum (Fal1 and
Fal2 primers), and 65uC for P. vivax (Viv1 and Viv2 primers) or P.
malariae (Mal1 and Mal2 primers). The fragments obtained for P.
vivax were of 120 bp, whereas for P. falciparum and P. malariae were
205 bp and 144 bp, respectively. The oligonucleotide sequences of
each primer used are listed in Table 2. The products were
visualized in 2% agarose gel stained with ethidium bromide. One
uninfected blood sample was included for every twelve samples
processed to control for cross-contamination. Fifteen percent of
positive PCR samples were re-tested to confirm the amplification
of plasmodial DNA. All tests were performed and confirmed at our
main laboratory at the Centro de Pesquisas Gonc ¸alo Moniz,
Brazil.
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Figure 2. Correlations between plasma SOD-1 or TNF-alpha concentrations and laboratory parameters of malaria severity.
Correlation of SOD-1 or TNF-alpha with several laboratory parameters in symptomatic vivax malaria patients (n=69). Column at left (A, C and E):
Correlations of SOD-1 with parasitaemia (A), plasma creatinine (C) and alanine amino-transaminase (ALT; E). Column at right: Correlations of TNF-
alpha to parasitaemia (B), plasma creatinine (D) and ALT (F). Correlation between TNF-alpha and SOD-1 plasma protein levels is shown in G. The
statistical significances were calculated using the Spearman test. The values of p and r are illustrated in each graph.
doi:10.1371/journal.pntd.0000650.g002
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Plasma levels of TNF-alpha were measured using the Cytomet-
ric Bead Array - CBAH (BD Biosciences Pharmingen, USA)
according to the manufacturer’s protocol, with all samples run in a
single assay. The flow cytometric assay was performed and
analyzed by a single operator, and standard curves were derived
from cytokine standards. The minimum limit of detection was
3.7 pg/mL.
Laboratory assessment of organ dysfunction
Plasma measurements of creatinine, alanine amino-transami-
nase (ALT) and haemoglobin were made at the clinical laboratory
of Faculdade Sa ˜o Lucas and at the Laborato ´rio LPC (Salvador,
Bahia. Brazil).
Plasma superoxide dismutase measurements
SOD-1 plasma concentrations were measured using the Cu/Zn
Superoxide Dismutase ELISA Kit according to the manufacturer’s
protocol (Calbiochem, EMD chemicals, Darmstadt, Germany).
Briefly, human serum was diluted 1:200 in PBS and distributed in
a sensitized 96-wells plate. The samples were incubated for one
hour at room temperature with HRP-conjugated anti-Cu/Zn
SOD antibody. A colorimetric substrate was added for ten
minutes, being the system protected from intense light. The
reaction was stop and the plate read at 450nm. The SOD activity
assay was performed using the Superoxide Dismutase Colorimet-
ric Assay Kit according to the manufacturer’s protocol (Cayman
chemical, Ann Arbor, MI, USA). Briefly, radical detector was
added to a sensitized 96-wells plate. Pre-diluted (1:50) samples
were distributed in wells. The reaction was started using Xanthine
Oxidase, and the plate was read after twenty minutes at 450nm.
One unit of SOD is defined as the amount of enzyme needed to
exhibit 50% dismutation of the superoxide radical.
Statistical analysis
The Kruskal-Wallis test with Dunn’s multiple comparisons or
linear trend analysis was used to compare SOD-1 and TNF-alpha
levels according to different clinical presentations of vivax malaria
infection. The Mann-Whitney test was used to verify differences
between asymptomatic and symptomatic, between mild and severe
vivax malaria or between P. vivax and P. falciparum infections.
Correlations between SOD-1 or TNF-alpha levels and severity
factors were performed using the Spearman test. Receiver-
operator characteristic (ROC) curves with C-statistics were used
to establish the threshold value of SOD-1 and TNF-alpha able to
discriminate between mild and severe infection. A p value,0.05
was considered statistically significant.
Results
Increased vivax malaria severity was associated with higher
plasma levels of SOD-1 (P,0.0001; Figure 1A and 1B), with
similar trend being noted with regard to SOD activity (P,0.01 for
linear trend; data not shown). Considering individuals with mild
and severe infections together (n=69), increased SOD-1 protein
levels were correlated with higher parasitaemia (r=0.77, p=0.03;
Figure 2A), while this correlation did not reach significance for
TNF-alpha (r=0.68, p=0.07; Figure 2B). In addition, spleno-
megaly and hypotension were more prevalent in patients with high
SOD-1 and TNF-alpha levels compared to those with low levels of
both factors (43.2% vs. 5.1% respectively; Fisher’s test p=0.02).
Correlation between SOD-1 protein levels and plasma creatinine
measurements was r=0.72 (p=0.03; Figure 2C), while the
correlation between TNF-alpha and creatinine did not achieved
statistical significance in the cohort under investigation in this
study (r=0.68, p=0.06; Figure 2D). Furthermore, a similar
pattern was observed regarding the correlation of ALT with SOD-
1 protein levels (r=0.81, p=0.03; Figure 2E) or TNF-alpha (r=0.
75, p=0.03; Figure 2F). SOD-1 protein levels were also directly
associated with systemic TNF-alpha (r=0.57, p,0.0001;
Figure 2G). All individuals with severe disease presented with
anemia at the time of hospitalization (haemoglobin mean:
6.261.4), while in those with mild infection, only 14/50 were
anemic (haemoglobin mean: 12.562.0). In agreement with
previous findings on P. falciparum [3] and P. vivax [4] infections,
individuals with severe malaria displayed higher plasma levels of
TNF-alpha than those with asymptomatic parasitaemia or mild
disease (Figure 1B). Within the individuals presenting with severe
disease who successfully recovered after in-hospital care (n=13),
the systemic levels of both SOD-1 and TNF-alpha decreased at
least two fold during the seventh day of anti-malarial treatment
(p=0.0005 and p=0.001, respectively; Figure 3). We also assessed
the possibility of estimating threshold levels of TNF-alpha and
SOD-1 to discriminate between asymptomatic and symptomatic
infection. As expected, individuals with symptomatic infection
(mild or severe) presented higher levels of both TNF-alpha and
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Figure 3. Effect of anti-malaria treatment on plasma concen-
trations of SOD-1 and TNF-alpha in individuals with severe
vivax malaria. Plasma levels of SOD-1 protein (red boxes, left Y axis)
and TNF-alpha (blue boxes, right Y axis) were estimated before
treatment (at admission to the Hospital) and after seven days of in-
hospital treatment with intravenous quinine and hemodynamic support
in individuals with severe vivax infection who successful recovered
(n=13). Boxes represent median and interquartile interval; whiskers
represent maximum and minimum values. Wilcoxon matched pairs test
was performed to calculate the statistical significance. P values are
plotted in each graph.
doi:10.1371/journal.pntd.0000650.g003
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however, was a better marker than TNF-alpha (Figure 4A).
Moreover, TNF-alpha and SOD-1 levels were elevated in
individuals with severe disease compared to mild disease
(Figure 1B). SOD-1 was also more powerful than TNF-alpha in
predicting severe disease (Figure 4B). In an attempt to address if
the plasma levels of both SOD-1 and TNF-alpha were useful to
discriminate P. vivax from P. falciparum malaria, we compared
plasma samples from individuals presenting with mild symptom-
atic vivax malaria and age matched individuals with symptomatic
P. falciparum infection. Neither SOD-1 nor TNF-alpha could
differentiate between the infections (Figure 5).
Discussion
This study is the first to examine the use of plasma SOD-1 levels
as a surrogate marker of P. vivax malaria severity. SOD-1 is an
important participant in the oxidative stress responses [6]. It has
been implicated in several other diseases and infections [13–17],
and its plasma levels could be a sensitive indicator of inflammatory
processes. More recently, SOD-1 has been found to play a
deleterious role in cutaneous leishmaniasis, as the interferon-beta
inhibition of leishmanicidal activity was mimicked by SOD-1 and
antagonized by either pharmacological or small interfering RNA-
mediated inhibition of SOD-1 [18]. SOD-1 levels were much
more effective in predicting vivax malaria severity than TNF-
alpha, a major cytokine related to malaria clinical severity in P.
vivax infections [19]. For discrimination of mild infection, the use
of SOD-1 improves the correct case detection by more than 45%
compared with the use of TNF-alpha, in addition to being a better
identifier of negative cases. Furthermore, SOD-1 has a higher
sensitivity than TNF-alpha in predicting severe vivax malaria,
indicating also a higher likelihood ratio to discriminate this clinical
condition. This suggests that SOD-1 can serve as an additional
and innovative tool in the clinical approach to P. vivax malaria
cases. The measurements of both SOD-1 and TNF-alpha in the
plasma samples are performed using simple ELISA-based kits. It is
possible then that costs may be similar depending on the demand.
Measuring SOD-1 levels could be used in two situations: (i)
identification of patients with severe disease before the develop-
ment of fatal outcomes and (ii) monitoring the success of therapy
and clinical recovery. The viability of applying this methodology
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diagnostic algorithm.
Whether this anti-oxidant enzyme could be used as a marker of
disease severity in P. falciparum infections was not evaluated here,
and should be tested in future investigations. However, in
individuals presenting with mild disease, plasma SOD-1 levels
could not differentiate between P. vivax and P. falciparum infections.
This suggests that these two parasites may share more similar
pathogenetic mechanisms than previously realized.
SOD-1 represents an important defense against oxidative stress
within a cell [16,17]. Furthermore, superoxide radicals are the
main ROS produced during acute malaria [5]. The role of SOD-1
in vivax malaria could be either protective or deleterious with
regard to the infection outcome. SOD-1 levels may be a reflection
of an active injury mechanism or, alternatively, may indicate a
counter-regulatory response to the generation of superoxide
radicals. Supplementation of SOD-1 protects endothelial cells
against the P. falciparum-induced oxidative response and apoptosis
in vitro [19]. Nevertheless, during experimental malaria, mice
overexpressing SOD-1 develop oxidative injury associated with
increased vulnerability to P. berghei [7]. Patients with acute non-
complicated P. falciparum or P. vivax malaria have less catalase
activity then non-infected individuals but higher SOD activity [8].
Reduced catalase activity together with increased SOD activity
may result in the accumulation of H2O2, the release of hydroxyl
radicals and increased tissue damage during severe malaria.
Although investigations analyzing more patients with broader
clinical outcomes are necessary, SOD-1 plasma protein levels
seems to represent a useful marker in predicting vivax malaria
severity based on the oxidative response status.
Limitations
This study illustrates the possibility of using SOD-1 levels as a
severity biomarker in human P. vivax malaria and highlights the
likelihood of exploring the future use of the plasma SOD-1 levels
as an effective marker of malaria severity. To validate our results,
studies investigating samples from different endemic areas are
crucial, as local health conditions such as co-infections may limit
the effective use of a biomarker. A possible advantage of
measuring SOD-1 levels as part of the clinical management in
endemic areas cannot be assumed from our results. The use of the
SOD-1 as a reliable marker also depends on future field
interventions in which the pre-test prediction and cost-effective-
ness should be considered. In addition, the specific role of SOD-1
in the immunopathogenesis of severe vivax malaria was not
explored in this study and is still being addressed by our group.
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